Perazine showed no clear difference in overall tolerability Leaving the study early due to adverse events compared with other antipsychotics (low certainty).
It is very uncertain whether group C other: family treatment changes satisfaction with treatment: leaving the study early FACT Long‐term compared with enhanced care (very low certainty).
COMPARISON 1: CBT+ STANDARD CARE showed no clear difference in satisfaction with treatment: 1. Leaving the study early ‐ long term compared with STANDARD CARE ALONE (moderate certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
Paliperidone palmitate probably leads to higher leaving the study early ‐ lack of efficacy Reported by trial author compared with risperidone long‐acting injection (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).
CBT may leads to lower satisfaction with treatment ‐ leaving the study early for any reason compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
It is very uncertain whether perazine changes acceptability of treatment Leaving the study early due to any reason compared with placebo (very low certainty).
FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
YOGA showed no clear difference in leaving the study early Leaving the study early: participants lost to compared with STANDARD CARE (moderate certainty).
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).
It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).
Group A: omega‐3 fatty acids showed no clear difference in satisfaction with treatment: leaving the study early Long‐term… compared with placebo (low certainty).